Introduction Biologic treatments are increasingly being used in the management of
moderate to severe plaque psoriasis (PSO). Bimekizumab is a selective inhibitor of both …

Importance Recent studies have shown an association between psoriasis and nonalcoholic
fatty liver disease (NAFLD) in US inpatients, but the association is still unclear in the …

Purpose of the article Psoriasis is a chronic, immune-mediated, skin disease with a
significantly negative impact on patients' quality of life. Moderate-to-severe disease often …

There is increasing interest in the association between psoriasis and non-alcoholic fatty liver
disease (NAFLD), which is a prevalent liver disease characterized by excessive fat storage …

Psoriasis is an incurable skin disease that develops in about two-thirds of patients before the
age of 40 and requires lifelong treatment; its pathological mechanisms have not been fully …

The management of plaque psoriasis that affects difficult-to-treat areas can be challenging.
Biologics have become the treatment of choice for moderate-to-severe plaque psoriasis …

Background. Patients with psoriasis need long‐term medication to control their condition.
Recent studies suggest that changing the intestinal flora may be a potential treatment …

Methotrexate (MTX) is one of the first-line drugs used for the treatment of moderate to severe
psoriasis. However, low bioavailability and systemic side effects of traditional oral and …

Several studies have described increased risk ratios of certain types of malignancies in
patients with severe psoriasis. Among these, the lymphoproliferative disorders, including …

Background There remains an unmet need for oral medications that are safe and efficacious
for long‐term management of chronic inflammatory skin diseases (CISD). Inhibition of …